InvestorsHub Logo
Followers 45
Posts 1514
Boards Moderated 0
Alias Born 11/25/2013

Re: dukesking post# 409283

Friday, 05/19/2023 8:12:19 AM

Friday, May 19, 2023 8:12:19 AM

Post# of 427301
Duke
? What CVD indication? R-IT patents are completely worthless. Whether the pt gets gV or V completely depends on exclusivity contracts negotiated with the Pt’s payer (insurance/PBM). Indication is 100% (not even 99%) irrelevant. Generics are being used “off label” for CVD regardless of any technical FDA indications.
Are there still people on this board who think either the patents or “approved indications” has ANY relevance or significance? The insurance company decides what the Pt gets and they ONLY care about price. HealthNet might have been pushed (via lawsuit) to chose V but I’m sure Amarin gave them a better price as part of the deal.
Exclusivity deals negotiated by KM is the only thing keeping market share over 10%.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News